Navigation Links
Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference

Conference will be held Feb. 11-13 at the Waldorf-Astoria Hotel in New York


NEW YORK, Jan. 24 /PRNewswire/ -- Gerson Lehrman Group (GLG) and the Biotechnology Industry Organization (BIO) today announced a collaborative agreement designed to strengthen the access to clinical information and insights at the tenth annual BIO CEO & Investor Conference.

"We're thrilled to have this unique partnership opportunity with BIO in their tireless efforts to increase the relevant and timely dissemination of some of the most highly technical and challenging scientific issues of today," said Alexander Saint-Amand, Chief Executive Officer of GLG. "Our company's long-standing mission is to empower decision-makers by connecting them to the academic and industry leaders driving innovation and productivity in our global economy."

Through this partnership, BIO will tap into GLG's network of experts from around the world in order to identify the most relevant thought leaders to discuss the latest issues and trends affecting drug development and clinical design in the biotechnology industry.

"Gerson Lehrman Group is an ideal partner for BIO's annual investment conferences with deep access to the clinical experts and investigators who can bring insights to pipeline research and current clinical practices," said James C. Greenwood, president and CEO of BIO. "Our Therapeutic Workshops and Business Roundtable discussions focus on educating investors and industry management on the issues that face product innovation, capitalization and commercialization."

The BIO CEO & Investor Conference is the largest independent biotechnology investor conference focused on publicly-traded companies. The conference features issue-oriented plenary sessions, educational sessions on therapeutic areas and business issues, company presentations, one-on-one meetings, and networking opportunities.

To see the latest updates on 2008 programming and speakers for BIO CEO & Investor Conference, please visit

About Gerson Lehrman Group

Gerson Lehrman Group (GLG) provides technology and services to support a marketplace for expertise. Since 1998, its platform for consultation and collaboration has helped the world's leading financial services firms, consultancies, corporations, and nonprofits find, engage, and manage experts in a broad range of industries and disciplines. GLG's unparalleled network of the world's leading expert consultants, known as the GLG Councils, includes more than 175,000 subject-matter experts who educate and provide insight to decision-makers through a wide range of consulting methods, including telephone consultations, expert surveys and seminars. GLG has invested in one of the world's most sophisticated infrastructures for expert recruiting and compliance. For more information about GLG, please visit

About BIO and the Tenth Annual BIO CEO & Investor Conference

Now in its tenth year, the BIO CEO & Investor Conference is the largest independent biotechnology investor conference focused on publicly-traded companies. The conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities. The conference is hosted by the Biotechnology Industry Organization (BIO), representing more than 1,150 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO produces the BIO International Convention, the world's largest gathering of the biotechnology industry.


Gerson Lehrman Group

Margaret M. Molloy

212 880-6569

SOURCE Gerson Lehrman Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group
2. Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network
3. Animal Protection Groups Condemn FDAs Endorsement of Animal Cloning
4. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
5. The Jordan Company, L.P. Has Teamed with the Management of Haas TCM Inc. to Form Haas TCM Group Inc.
6. Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference
7. Bioscience Group Warns Policymakers Against Complacency
8. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
9. Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei
10. The Ensign Group, Inc. Declares Quarterly Dividend of $0.04 Per Share
11. AG Mednet to Provide Image Network for Southwest Oncology Group
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):